Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Crovalimab - Chugai Pharmaceutical/Roche

Drug Profile

Crovalimab - Chugai Pharmaceutical/Roche

Alternative Names: Anti-C5 recycling antibody - Chugai Pharmaceutical/Roche; CH-7092230; Piasky; RG 6107; RO 7092230; RO-7112689; RO-711269; RO7112689/F01; SKY-59

Latest Information Update: 09 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chugai Pharmaceutical
  • Developer Chugai Pharmaceutical; Roche
  • Class Antianaemics; Monoclonal antibodies; Urologics
  • Mechanism of Action Complement C5 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Registered Paroxysmal nocturnal haemoglobinuria
  • Phase III Atypical Haemolytic Uraemic Syndrome
  • Phase II Sickle cell anaemia
  • Phase I Lupus nephritis

Most Recent Events

  • 09 May 2024 Chugai Pharmaceuticals and Roche plans to file regulatory application for the approval of crovalimab for Atypical hemolytic uremic syndrome (SC) in 2026 (Roche pipeline, May 2024)
  • 09 May 2024 Roche and Chugai Pharmaceuticals plans to file regulatory application for Sickle cell anaemia (SC) in the year 2027 and beyond (Roche pipeline, May 2024)
  • 26 Mar 2024 Registered for Paroxysmal nocturnal haemoglobinuria in Japan (SC)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top